For HR+/HER2-negative BC, where pCR is less frequent and adjuvant endocrine therapy is the cornerstone of systemic treatment, there appears to be a trend towards improved survival, especially in higher-grade and/or luminal B subtypes (36). This evidence concerns the gene ERBB2 and breast cancer.